ClinicalTrials.gg
Status unknownNCT04905940Updated Jul 27, 2022

Evaluation of Clinical and Cost-effectiveness of Different Mouthwashes on Controlling Halitosis Among a Group of Egyptian Children

An interventional study of Turmeric mouthwash in Halitosis, sponsored by Cairo University. Status unknown. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
8 Years to 12 Years
Sex
All
01

Study summary

To evaluate the clinical and cost-effectiveness of mouthwash containing Curcuma longa (Turmeric extract) versus mouthwash containing essential oils and Placebo mouthwash on controlling Halitosis among a group of Egyptian children.

Read the detailed description

For both interventions:

  1. Eligibility screen and patient selection according to the inclusion and exclusion criteria.
  2. Readings for halitosis will be recorded using Tanita HC-312F Fitscan Portable Breath Checker (Tanita Corporation, Japan) that shows red, yellow and green colors indicating halitosis degree.

    • Green color=no odour
    • Yellow color=moderate odour
    • Red color=intense odour Children with yellow or red colored results will be included.
  3. Participants will be provided with information regarding the risks and benefit of the study and written informed consent will be obtained.
  4. Intra and extra-oral examinations and Baseline records photographs, caries assessment by using DMF, gingival condition assessment using Simplified oral hygiene index and personal data collection.
  5. Participating children will be offered a full mouth restorative treatment, if needed, before starting the trial to exclude that halitosis comes from food impaction in carious teeth.
  6. In another visit, after the full mouth rehabilitation, readings for halitosis will be re-recorded using color coded Tanita HC-312F Fitscan Portable Breath Checker (Tanita corporate, Japan). Patients who will get green colored result will be excluded from the study as the cause of halitosis in those patients would be food impaction in carious teeth.
  7. Allocation of the participants who will score more than 2 into either one of three groups; A, B or C. i. A for Experimental group (Turmeric mouthwash) ii. B for first comparator (Essential oil mouthwash) iii. C for second comparator (Placebo)

    Allocation will be concealed by withdrawing a sealed opaque envelope containing four times folded paper containing the type of mouth wash that will be used. This will decrease performance bias as the operator will not know the group of the participant until taking the score of the patients and finishing the restorative treatment. Blinding of the operator will not be needed as the readings will be objective and recorded using the device (Tanita device) not by the operator (organoleptic method).

  8. All mouth rinse samples (experimental and comparators 1\&2) will be put into identical white opaque plastic bottles labelled with the codes A, B or C for the blinding of the participant. Group A: The experimental sample is a Turmeric mouthwash which will be prepared by dissolving 10 mg of Turmeric extract in 100 mL of distilled water and 0.005% of flavouring agent peppermint oil (Sharma, 2016). Group B: The first comparator will be the commercial Miswak Listerine mouthwash. Group C: The second comparator will be a placebo mouthwash and will be prepared with peppermint oil and distilled water; essentially the same contents as those in the experimental mouthwash except for the turmeric powder.
  9. Every participant will use 2 mouthwash bottles of the same group label that they were allocated to. The first bottle according to their allocation. Patients will be given standard written oral hygiene instructions and mouth washing instructions to rinse twice daily with 10 ml for 1 minute under their parents" supervision for two weeks.
  10. The first follow up visit after two weeks, the halitosis score will be recorded by using the Tanita device for numerical record and by asking the parent if there is a bad odour or not. Patients then will be instructed to stop rinsing for the next two weeks while maintaining other oral hygiene instructions.
  11. The second follow-up visit after 4 weeks, patients will be given the second bottle and instructed to rinse twice daily with 10 ml for another two weeks.
  12. The last follow up visit will be after 6 weeks and the final Halitosis score will be recorded.
02

Conditions studied

  • Halitosis

Browse trials for

03

In context

Halitosis

93 studies on the registry are indexed under Halitosis; 17 are open to participants now.

This study's planned enrollment of 30 is below the median of 45 across 79 interventional studies indexed under Halitosis.

Browse Halitosis studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 8-12 years old.
  • Cooperative children.
  • Both genders.
  • Medically free to exclude systemic cause of halitosis.
  • Bad breath

Exclusion criteria

Exclusion Criteria:

  • Children using any other oral hygiene aid other than routine teeth brushing.
  • Children with a known history of allergy to any mouthwash or drug.
  • Parents refuse to participate in the trial.
  • Treatment by antibiotic within one month before the trial(Pham \& Nguyen, 2018).
  • Abscess, draining sinus, cellulitis, or other conditions requiring emergency dental treatment.
  • Children using fixed or removable orthodontic appliances or dentures.
  • Children with a history of deleterious oral habits of mouth breathing.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Turmeric mouthwash

    Evaluation of cost-effectiveness of turmeric mouthwash in controlling halitosis

    Drug: Turmeric mouthwash

  • Active comparator
    Essential oil mouthwash

    Evaluation of cost-effectiveness of essential oil mouthwash in controlling halitosis

    Drug: Turmeric mouthwash

  • Placebo comparator
    Placebo mouthwash

    Evaluation of cost-effectiveness of placebo mouthwash in controlling halitosis

    Drug: Turmeric mouthwash

Interventions

06

What researchers measure

Primary outcomes

  1. Questionnaire for Patient related side effects

    the measuring unit will be binary (yes/no) from the parent and child. While using the mouthwash: 1. Is the Child's quality of life changed for the better? 2. Acceptance and safety of the mouth wash

    Time frame: 45 days

Secondary outcomes

  1. Cost-effectiveness

    Economic and Clinical effectiveness of turmeric mouthwash Cost effectiveness will be measured according to ICER (Incremental cost-effectiveness ratio)

    Time frame: 45 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04905940
Lead sponsor
Cairo University
Responsible party
Eman Mohammed Elsaeed Ahmed (principle investigator, Cairo University) — Principal investigator
First posted
May 28, 2021
Start date
Aug 1, 2022 (estimated)
Primary completion
Dec 1, 2022 (estimated)
Completion
Dec 1, 2022 (estimated)
Last update
Jul 27, 2022

Study contacts

Eman M Elsaeed, B.Sc
Contact
eman.elsaeed@dentistry.cu.edu.eg
+201000994721
Passant Nagi, PHD
Contact
Passant.nagi@dentistry.cu.edu.eg
+201280557107

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Turmeric extract · Curcuma longa

Start the discussion